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Abstract
Background: Metastasis is a major cause of death in human colorectal cancer patients. However, the contribution
of chemokines in the tumor microenvironment to tumor metastasis is not fully understood.
Methods: Herein, we examinined several chemokines in colorectal cancer patients using chemokine ELISA array.
Immunohistochemistry was used to detect expression of CXCL5 in colorectal cancer patients tissues. Human
HCT116 and SW480 cell lines stably transfected with CXCL5, shCXCL5 and shCXCR2 lentivirus plasmids were used in
our in vitro study. Immunoblot, immunofluorescence and transwell assay were used to examine the molecular
biology and morphological changes in these cells. In addition, we used nude mice to detect the influence of
CXCL5 on tumor metastasis in vivo.
Results: We found that CXCL5 was overexpressed in tumor tissues and associated with advanced tumor stage as
well as poor prognosis in colorectal cancer patients. We also demonstrated that CXCL5 was primarily expressed in
the tumor cell cytoplasm and cell membranes, which may indicate that the CXCL5 was predominantly produced by
cancer epithelial cells instead of fibroblasts in the tumor mesenchyme. Additionally, overexpression of CXCL5 enhanced
the migration and invasion of colorectal cancer cells by inducing the epithelial-mesenchymal transition (EMT) through
activation of the ERK/Elk-1/Snail pathway and the AKT/GSK3β/β-catenin pathway in a CXCR2-dependent manner. The
silencing of Snail and β-catenin attenuated CXCL5/CXCR2-enhanced cell migration and invasion in vitro. The elevated
expression of CXCL5 can also potentiate the metastasis of colorectal cancer cells to the liver in vivo in nude mice
intrasplenic injection model.
Conclusion: In conclusion, our findings support CXCL5 as a promoter of colorectal cancer metastasis and a predictor
of poor clinical outcomes in colorectal cancer patients.
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Background
Colorectal cancer (CRC) is one of the most common
cancers worldwide [1]. Although many breakthroughs in
the diagnosis and treatment of CRC have been made
over the past few decades, CRC-related mortality re-
mains high [2]. As the major cause of death for most
cancer patients, tumor metastasis is an important
adverse factor in the treatment and prognosis of CRC
patients [3]. Tumor metastasis is a complicated and
multistep process which requires the ability of the tumor
to migrate and invade [4, 5]. Despite an increase in our
understanding of cell biology and the identification of
many metastasis-related molecules [6], the chemokine-
related alterations in the tumor microenvironment that
promote CRC metastasis remain largely unknown.
Chemokines are a multifunctional superfamily of small
proteins that bind to G protein-coupled receptors on
target cells. CXCL5 belongs to a subset of CXC chemo-
kines and functions as the ligand for CXCR2 [7]. By
binding to CXCR2, CXCL5 mediates various cellular be-
haviors including neutrophil trafficking, tumor cell mi-
gration and invasion [8]. Recent studies have reported
that TNF-α-induced mesenchymal stromal cells (MSCs)
can secrete CXCL5 to recruit CXCR2+ neutrophils that
promote breast cancer metastasis [9]. These findings
indicate that CXCL5 can act as a protumoral molecule
in a paracrine way through recruiting immune cells.
However, the mechanisms underlying the role of CXCL5
on CRC remain unknown.
In our study, we examined the expression of several
chemokines in CRC tissues and found that CXCL5 was
highly expressed in CRC tissues. In addition, we investi-
gated the influence of CXCL5 on the survival of CRC
patients and showed that CXCL5 levels were negatively
correlated with prognosis. Furthermore, we also revealed
that CXCL5 secreted by tumor cells was able to promote
CRC migration through ERK/Elk-1/Snail-mediated EMT
(Epithelial mesenchymal transition) and invasion via the
AKT/GSK3β/β-catenin/MMP7 pathway in a CXCR2-
dependent manner. Our study conclusively demonstrates
that the overexpression of CXCL5 in CRC is able to pro-
mote CRC metastasis and predicts a poor outcome in
patients with CRC, indicating that CXCL5 may serve as
a potential therapeutic target.
Results
Chemokine expression profiles in CRC tissue
To understand the expression profiles of the chemokines
in CRC, we compared the distinct changes in several
chemokines between the tumor and peritumoral normal
tissues using a chemokine ELISA array. By setting a
threshold of at least a 2-fold upregulation, the number
of upregulated chemokines ranged from 3 (Sample 1) to
18 (Sample 4) in the various samples (Fig. 1a, b and c).
This may be due to the different pathological stages of
these samples (Sample 1:I vs Sample 4:IV). The number
of upregulated chemokines increased with tumor pro-
gression. Five chemokines (CXCL8, CXCL1, CXCL5,
CCL2, and CCL15) were upregulated in more than three
samples (Fig. 1a). The association between CXCL8,
CXCL1 and tumor metastasis has been thoroughly
described in previous studies [10, 11]. Therefore, we
primarily focused on the function of CXCL5.
CXCL5 is upregulated in human CRC tissue
The preliminary ELISA results verified that CXCL5 is
upregulated in CRC tissues (Fig. 1). To confirm the in-
creased expression of CXCL5 in human CRC tissues, we
examined the mRNA and protein levels of CXCL5 in 29
paired CRC samples. In total, either 23 or 22 patients
had high relative expression levels of CXCL5 in mRNA
or protein level (Fig. 2a; Additional file 1: Figure S1A).
The CXCL5 mRNA levels in the tumors were sig-
nificantly higher than those in the peritumoral normal
tissues (Fig. 2b). The expression levels of CXCL5 were
also examined in tissue microarrays including 78 pairs of
CRC samples. We selected a staining score of 4.5 as the
cut-off value using X-tile software (Additional file 2:
Figure S2). In this cohort, CXCL5 expression was upreg-
ulated in approximately 61.5% (48/78) of the paired
tissues (Additional file 3: Table S4, Fig. 2c and d). More-
over, the expression of CXCL5 was primarily localized to
the tumor cells rather than the mesenchymal portion of
the cancerous tissue (Fig. 2c).
High expression of CXCL5 is correlated with poor
prognosis in CRC patients
We next analyzed the associations between CXCL5 ex-
pression and clinical features of CRC patients. The ana-
lysis revealed that the high expression of CXCL5 was
significantly correlated with tumor size (P = 0.047),
Dukes’ stage (P = 0.003), tumor invasion (P = 0.009),
lymph node localization (P = 0.002), and liver metastasis
(P = 0.022) (Additional file 3: Table S4). Kaplan-Meier
survival analysis demonstrated that CXCL5high patients
had a poor overall survival (OS) compared to those with
low CXCL5 expression (P = 0.032) (Fig. 2e). In addition,
CRC patients with increased expression of CXCL5 were
less likely to reach disease-free survival (DFS) status than
CXCL5low patients (P = 0.001) (Fig. 2f ). The univariate
COX regressive analysis indicated that CXCL5 was asso-
ciated with OS (P = 0.019) and DFS (P = 0.004). However,
the multivariate analysis showed that CXCL5 and Dukes’
Stage were independent prognostic factor for DFS but
not for OS (Additional file 3: Table S5). Based on these
results, we constructed a nomogram to predict DFS 3
and 5 years after surgery for CRC patients by integrating
all of the significant independent factors for DFS
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(Fig. 2g). The calibration plot for the predicted probability
of DFS 3 or 5 years after surgery revealed an optimal
consistency between the prediction by nomogram and the
actual survival rate (Additional file 1: Figure S1B and C).
Together, these results demonstrate that CXCL5 is as-
sociated with CRC progression and metastasis. More-
over, CXCL5high patients have a poor prognosis, and
CXCL5 is an independent prognostic factor of DFS.
Tumor-derived CXCL5 promotes CRC cell migration via
EMT in a CXCR2-dependent manner
Fibroblasts are regarded as key determinants in the ma-
lignant progression of cancer through the secretion of
various chemokines, including CXCL5 [12]. However, we
found that CXCL5 was primarily secreted by cancer cells
in CRC. In the IHC assay described above, we observed
CXCL5 staining primarily in cancer cells. By counter-
staining the fibroblasts, we further found that, although
CXCL5 staining was observed in the tumor mesen-
chyme, CXCL5 was primarily expressed in the tumor le-
sions rather than the fibroblasts, which were visualized
with the fibroblast marker α-smooth muscle actin
(αSMA) (Fig. 3a and b). These results indicate that
CXCL5 is primarily secreted by cancer cells. To further
investigate this phenomenon, we examined the expres-
sion of CXCL5 and its receptor CXCR2 in various CRC
cell lines. An elevated expression of CXCL5 was ob-
served in the CRC cell lines compared with the normal
colon epithelial NCM460 cell line. CXCL5 was highly
expressed in SW480, as well as CaCo2 cells, and a low
expression was observed in the SW620 and HCT116
cells (Fig. 3c). The levels of CXCL5 in the supernatants
of the CRC cell lines as detected by ELISA were con-
sistent with the results of the immunoblots (Additional
file 4: Figure S3A). All four cell lines had high levels of
CXCR2 (Fig. 3c), and we chose the HCT116 and SW480
cell lines for further investigation. Stable ectopic expres-
sion and down-regulation of CXCL5, as well as knock-
outs of CXCR2, were induced in the HCT116 and
SW480 cells, and expression was confirmed by immuno-
blotting (Fig. 3d) and immunofluorescence staining
(Additional file 4: Figure S3B).
We next investigated the biological changes of cells
with high and low expression of CXCL5 and found that
Fig. 1 Expression profiles of chemokines in four CRC tissues. a A heat map displays the hierarchical clustering of the chemokine expression
profiles. b An overlapping pie chart displays the distribution of chemokines in the four samples. c The protein microarray shows the expression of
CXCL5, which was the primary focus of this study. The representative image is from sample 3. These four patient samples are selected according
to their pathological stages which rages from Dukes I to Dukes IV. Pathological stages of the four tissues tested are, respectively: sample 1, Dukes
I; sample 2, Dukes III; sample 3, Dukes II; sample 4, Dukes IV
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the ectopic expression of CXCL5 in HCT116 cells
(HCT116CXCL5), as well as the down-regulated ex-
pression of CXCL5 in SW480 cells (SW480shCXCL5),
either promoted (in HCT116CXCL5) or inhibited (in
SW480shCXCL5) the migration of these two cell lines
compared with the control group. Additionally, the in-
hibition of CXCR2 in HCT116 cells (HCT116shCXCR2)
suppressed the ability to migrate and also reversed
migration-promoting behavior in HCT116CXCL5 cells
(HCT116CXCL5-shCXCR2). Similarly, the inhibition of
Fig. 2 Increased expression of CXCL5 in CRC tissues, Kaplan-Meier analysis and nomogram plots. a & b RT-PCR results showing high expression of
CXCL5 in CRC tissues. Data are showed by 2-ΔΔCt (a) and 2-ΔCt (b). c & d Representative immunohistochemistry images showing that CXCL5 is
highly expressed in 61.5% of the cancer tissues in tissue microarray (tissues used are different from Figs. 1 and 2a & b). Scale: 200 μm. ***P<0.001.
e & f Kaplan-Meier analysis of OS and DFS. The CXCL5high group has a worse prognosis in OS and DFS compared with the CXCL5low group.
g Nomogram to predict DFS 3 and 5 years after surgery. CXCL5 line: 1 represents positive staining; 0 represents negative staining. Stage line: 1, 2,
3 and 4 represent Dukes stage I, II, III and IV. Calculation: find their points on the “point line” according to the CXCL5 staining and Dukes stage.
Total points are equal to CXCL5 points plus Dukes stage points. The 3- or 5-year survival rates are indicated on the “3-year survival” line or “5-year
survival” line according to their total points. For example, for a patient with CXCL5 positive staining and Dukes II. CXCL5 point is 0, Stage point is
5.2, total point is 5.2, 3-year survival prediction is 78%, 5-year survival prediction is 52%
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CXCR2 in SW480 cells (SW480shCXCR2) and SW480shCXCL5
cells (SW480shCXCL5-shCXCR2) suppressed their migration
(Fig. 3e and f). These results indicate that the function of
CXCL5 is dependent on CXCR2. Moreover, we also ob-
served morphological changes in the CRC cells. As shown
in Additional file 4: Figure S3C, HCT116CXCL5 acquired a
mesenchymal, spindle-like morphology compared with
the HCT116shCXCR2, HCT116CXCL5-shCXCR2 and control
cells. These spindle-like characteristics were also observed
in the SW480shRNA cells, which had a high metastatic po-
tential. However, the SW480shCXCL5, SW480shCXCR2 and
SW480shCXCL5-shCXCR2 cells developed an epithelial cell-
like morphology and tended to accumulate in clusters.
Therefore, we hypothesized that CXCL5/CXCR2 promotes
Fig. 3 CXCL5 localization in CRC tissues, the expression of CXCL5 in CRC cell lines and CXCL5/CXCR2 promotes CRC cell migration through the
induction of EMT. a & b Immunohistochemistry and immunofluorescence images showing the location of CXCL5 and αSMA (marker of fibroblasts) in CRC
specimens. CXCL5 is mainly expressed in tumor tissue instead of mesenchymal tissue. c Immunoblots examining CXCL5 expression levels in CRC cell lines
and normal colon epithelial cell. d Representative data from the immunoblot analysis verifying the changes of CXCL5 or CXCR2 using a CXCL5-vector or
shRNA-inhibition of CXCL5 and CXCR2. e & f Representative images from the transwell migration assay in indicated CRC cells. Magnification, 200×.
Scale, 200 μm. Data represent the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. g Immunoblot analysis of EMT marker expression in indicated cells.
h Immunofluorescence images showing the changes in E-cadherin and Vimentin after different treatments with CXCL5-vector or shRNA-inhibition of
CXCL5 and CXCR2. Scale, 50 μm
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CRC cell migration by inducing EMT. To confirm our hy-
pothesis, we examined changes in EMT markers in these
cells. The results demonstrated that the upregulation of
CXCL5 in HCT116CXCL5 cells led to lower expression of
the epithelial markers E-cadherin and ZO-1 and higher
expression of the mesenchymal markers N-cadherin and
Vimentin (Fig. 3g and h). However, lower levels of
E-cadherin and ZO-1, as well as an upregulation of N-
cadherin and Vimentin, were observed in SW480shRNA
cells (ControlshRNA), which is a highly metastatic CRC cell
line. Elevated levels of E-cadherin and ZO-1, as well as re-
duced expression of N-cadherin and Vimentin, were also
observed in the SW480shCXCL5, SW480shCXCR2 and
SW480shCXCL5-shCXCR2 cells (Fig. 3g and h). These results
indicate that CXCL5 is able to promote CRC cell migra-
tion by inducing EMT in a CXCR2-dependent manner.
The CXCL5/CXCR2 axis induces EMT in CRC cells via the
ERK/Elk-1 pathway
Previous studies have shown that CXCR2 can be acti-
vated by CXCL5 or other ligands to stimulate cancer
progression through the activation of downstream path-
ways, such as JAK/STAT3, JNK, PI3K/AKT and ERK1/2
pathway [13, 14]. To analyze the mechanisms underlying
the induction of EMT by CXCL5/CXCR2, we examined
the activity of these pathways. As shown in Fig. 4a
and b, ectopic CXCL5 expression in HCT116CXCL5 cells
activated the ERK and AKT pathways, as indicated by the
upregulation of phosphorylated ERK1/2 (pERK1/2) and
AKT (pAKTSer473). Similarly, pERK and pAKT were also
highly expressed in SW480shRNA cells. As expected, low
levels of pERK and pAKT were observed in the
SW480shCXCL5 cells. Additionally, the knock-down of
CXCR2 inhibited the phosphorylation of ERK and AKT.
Furthermore, the effects of CXCL5 were inhibited in the
HCT116CXCL5-shCXCR2 cells. These results indicated that
the phosphorylation of ERK and AKT was dependent on
CXCR2. Moreover, CXCL5 had no effect on the activation
of pSTAT3Tyr705 and pJNKThr183/Tyr185.
Next, we examined which of these two CXCL5-
activated pathways was able to induce EMT. We used
inhibitors of the ERK pathway (U0126) and the AKT
pathway (LY294002) to block the activity of these two
pathways. Our results demonstrated that the inhibition
of ERK pathway rather than AKT pathway changed the
cellular morphology and reversed the effects of CXCL5
on migration in HCT116CXCL5 and SW480shRNA cells
(Additional file 5: Figure S4). Based on these findings,
the effects of these two pathways on EMT markers were
further evaluated using immunofluorescence and im-
munoblotting. The results revealed that suppression of
the ERK pathway promoted the expression of E-
cadherin and ZO-1, as well as downregulated the expres-
sion of N-cadherin and Vimentin. However, inhibition of
the AKT pathway had little effect on these changes
(Fig. 4e and f). This is consistent with the results of im-
munofluorescence (Fig. 4c and d). The downstream pro-
tein Elk-1 has been confirmed to be an effector of the
ERK pathway [15], so we next investigated alterations of
this effector. Our results showed that Elk-1 phospho-
rylation (pElk-1Ser383) either increased or decreased with
the upregulation or downregulation of pERK in
HCT116CXCL5 and SW480shRNA cells, and the effect was
blocked after the knock-down of CXCR2. Meanwhile, in-
hibition of the ERK pathway decreased the levels of
pElk-1, which indicates that pElk-1 may act as down-
stream effector of the ERK pathway (Fig. 4e and f).
Altogether, these results indicate that the CXCL5/
CXCR2 axis is capable of promoting CRC cell migration
by inducing EMT. The mechanism behind this primarily
involves the ERK/Elk-1 pathway.
Snail is involved in the CXCL5/CXCR2-mediated
promotion of CRC cell migration and EMT and is
regulated by the CXCL5/CXCR2 axis via the ERK/Elk-1
pathway
Previous studies have demonstrated that transcription
factors, including Snail, Slug and ZEB1, which act as E-
cadherin repressors, are involved in controlling the EMT
transition [16, 17]. Consequently, to evaluate whether
CXCL5/CXCR2-mediated EMT was regulated by these
transcription factors, we assessed their expression pro-
files. Immunoblot data showed a significant increase in
Snail levels in HCT116CXCL5 cells and a decrease in
Snail levels in SW480shCXCL5, SW480shCXCR2 and
SW480shCXCL5-shCXCR2 cells. However, there were no ob-
vious alterations in Slug and ZEB1 expression (Fig. 5a).
We next investigated the influence of Snail on EMT
markers. The knock-down of Snail increased E-cadherin
expression and downregulated N-cadherin and Vimentin
levels in both HCT116 and SW480 cells. Snail shRNA also
reversed the effect of CXCL5 in HCT116CXCL5 (Fig. 5c, g
and h). Additionally, we observed a reversal of the epithe-
lial cell-like morphological change and an increase of mi-
grational cell number in the Snail-shRNA-transfected
wild-type HCT116 and HCT116CXCL5 cells. An opposite
effect was observed in SW480 groups (Fig. 5d, e and f).
Altogether, the above results support a causal role for
Snail in the CXCL5-induced and CXCR2-dependent EMT
process. Additionally, we also found that the level of Snail
was inversely downregulated in the U0126-HCT116CXCL5
group. Consistently, the use of U0126 in the SW480 group
also decreased the expression of Snail. Furthermore, there
were no obvious changes in Snail levels in the AKT path-
way inhibitor groups of both the HCT116 and SW480 cell
lines (Fig. 5b). Taken together, these results suggest that
the CXCL5/CXCR2 axis induces EMT to promote CRC
cell migration via the ERK/Elk-1/Snail pathway.
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The CXCL5/CXCR2 axis promotes CRC cell invasion
through the AKT/GSK3β/β-catenin/MMP7 pathway
We next assessed the contribution of the CXCL5/
CXCR2 axis to CRC cell invasion. We found that ectopic
expression of CXCL5 was able to promote cell invasion,
and the difference in the number of invading cells was
statistically significant compared with the control group
in HCT116. The knock-down of CXCR2 also reduced
the number of invading cells. Consistently, inhibition of
CXCL5 or (and) CXCR2 decreases invading cell number
in SW480 group (Fig. 6a and b). Several studies have
demonstrated that β-catenin is able to translocate to the
tumor cell nucleus and function as an oncogene to pro-
mote CRC cell invasion [18]. Consistently, our results
revealed that CXCL5 enhanced the translocation of
β-catenin to the nucleus in HCT116CXCL5 cells. The in-
hibition of CXCR2 led to an accumulation of β-catenin in
the cytoplasm instead of translocation to the nucleus.
However, β-catenin accumulated primarily in the nucleus
of the SW480shRNA cells, and CXCL5 and/or CXCR2 in-
hibition resulted in a cytoplasmic distribution of β-catenin
(Fig. 6c). After down-regulating the expression of β-
catenin in HCT116CXCL5 and SW480shRNA cells (Fig. 6d),
we found the inhibition of β-catenin eliminated the
CXCL5-induced invasion in HCT116CXCL5 and SW480
cells, as the number of invading cells was significantly
lower than in the control group (P < 0.01) (Fig. 6e and f).
These data indicate that CXCL5/CXCR2 may promote
Fig. 4 CXCL5/CXCR2 induces EMT in CRC cells via the ERK/Elk-1 pathway. a & b CXCL5 induces the phosphorylation of ERK and Akt in CRC cells
in a CXCR2-dependent manner. No differences are observed in STAT3 and JNK pathway. c & d Representative immunofluorescence images
showing that inhibition of the ERK pathway using U0126 upregulates E-cadherin expression and downregulates Vimentin expression in HCT116CXCL5
and SW480shRNA cells. Inhibition of the AKT pathway using LY294002 is not able to change expression of E-cadherin or Vimentin in HCT116CXCL5 and
SW480shRNA cells. Scale, 50 μm. e & f Immunoblots showing that inhibition of the ERK pathway using U0126 upregulates E-cadherin expression and
downregulates Vimentin expression in HCT116CXCL5 and SW480shRNA cells. Inhibition of the AKT pathway using LY294002 is not able to change the
expression of E-cadherin or Vimentin in HCT116CXCL5 and SW480shRNA cells. Changes in Elk-1 are consistent with changes in ERK1/2
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CRC cell invasion through the regulation of β-catenin, as
demonstrated by the redistribution of cytosolic and nu-
clear β-catenin.
As discussed above, the CXCL5/CXCR2 axis is able to
regulate both the ERK and AKT pathways. However, the
AKT pathway has minimal effects on CRC cell
migration. Thus, we hypothesized that the AKT pathway
may be involved in the regulation of CRC cell invasion.
Immunoblot results revealed that the upregulation of
pAKTSer473 in HCT116CXCL5 enhanced the expression of
β-catenin and the downstream factor pGSK3βSer9.
Knock-down of CXCR2 in HCT116 and HCT116CXCL5
Fig. 5 Snail is critical to CXCL5/CXCR2-mediated CRC migration. a Immunoblot analysis of Snail, Slug and ZEB1 levels in the indicated cells. CXCL5
is able to induce Snail expression. b Inhibition of the ERK pathway (U0126) instead of the AKT pathway (LY294002) downregulates Snail expression in
the indicated cells. c Downregulation of Snail inhibits CXCL5-induced downregulation of E-cadherin and upregulation of Vimentin and N-cadherin in
HCT116. Downregulation of Snail upregulates E-cadherin expression and downregulates Vimentin and N-cadherin expression in SW480. d Inhibition of
Snail altered the morphology of cells in both the HCT116CXCL5 and SW480 groups. e & f Inhibition of Snail decreased the number of migrating cells
in the indicated cell lines. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. g & h Immunofluorescence images show that
downregulation of Snail inhibits CXCL5-induced downregulation of E-cadherin and upregulation of Vimentin and N-cadherin in HCT116. Downregulation
of Snail upregulates E-cadherin expression and downregulates Vimentin and N-cadherin expression in SW480. Scale, 50 μm
Zhao et al. Molecular Cancer  (2017) 16:70 Page 8 of 15
Fig. 6 (See legend on next page.)
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cells blocked this process (Fig. 6g). Downregulation of
CXCL5 and/or CXCR2 in SW480 cells inhibited the
phosphorylation of AKTSer473, the expression of β-
catenin and pGSK3βSer9 (Fig. 6h). These results indicate
that CXCL5-enhanced phosphorylation of AKTSer473
may be able to increase β-catenin levels in CRC cells in
a CXCR2-dependent manner.
As previously reported, MMP7 may be one of the tar-
gets of β-catenin in CRC [19]. Consequently, we exam-
ined MMP7 expression in CRC cells. Our results
demonstrate that the regulation of MMP7 coincides with
alterations in β-catenin levels (Fig. 6g and h). Moreover,
we found inhibition of pAKTSer473 led to decrease of
MMP7. However, the inhibition of the ERK pathway by
U0126 has no effect on this process (Fig. 6i and j). Taken
together, these data indicate that CXCL5 is able to pro-
mote CRC cell invasion in a CXCR2-dependent manner.
This process may involve regulation of the AKT/GSK3β/
β-catenin/MMP7 pathway.
CXCL5/CXCR2 increases CRC liver metastasis in vivo
To determine whether the CXCL5/CXCR2 axis is involved
in CRC metastasis in vivo, we generated a liver metastasis
model using nude mice. Results revealed that more meta-
static nodules were observed in the HCT116CXCL5 group,
and fewer metastatic lesions were observed in the
HCT116shCXCR2 and HCT116CXCL5-shCXCR2 groups com-
pared with the control group. The difference in the num-
ber of nodules was statistically significant (Fig. 7a and b).
However, the SW480shCXCL5, SW480shCXCR2, and
SW480shCXCL5-shCXCR2 groups formed fewer metastatic
nodules compared with the control group. The number of
nodules in each group was significantly less than the con-
trol group (Fig. 7c and d). These indicate that CXCL5/
CXCR2 axis is able to promote CRC liver metastasis in
vivo. A schematic diagram of our study is shown in
Fig. 7e.
Discussion
Chemokines link the extra-tumoral microenvironment
to the tumor and facilitate the progression of CRC [20].
For this reason, we examined the expression of several
chemokines in CRC and preliminarily verified the up-
regulation of CXCL5 in CRC. Previous studies have
reported that CXCL5 produced by fibroblasts plays a
prominent role in the progression, growth and spread of
various types of cancer [15, 21]. However, in our study,
we revealed that CRC cells, rather than fibroblasts, are
able to secrete CXCL5. This promotes liver metastasis in
vivo and contributes to CRC cell migration via the ERK
pathway through the induction of EMT, as well as inva-
sion via the AKT pathway in vitro.
As described above, we first screened the expression
profiles of several chemokines. The functions of the
most upregulated chemokines have been studied in vari-
ous cancers, including CRC. We primarily concentrated
on CXCL5 in our study. Next, we employed two cohorts
of clinical samples to determine the levels of CXCL5 ex-
pression. Our results demonstrated that the expression
of CXCL5 was clearly up-regulated in CRC tissues. In
the second cohort, we linked the results to clinical
follow-up data. CXCL5 was significantly correlated with
tumor size, Dukes’ stage, tumor invasion, lymph node
localization, and liver metastasis. The upregulation of
CXCL5 in tumor tissues was also positively correlated
with a poor prognosis in CRC patients. CXCL5high pa-
tients had lower OS and DFS rates compared with
CXCL5low patients. In contrast, Frank et al. demon-
strated that the absence of CXCL5 expression in tumor
tissues was correlated with poor prognosis in CRC, and
they also found that CXCL5 was overexpressed in tumor
tissues [22]. They attributed these phenomena to intra-
tumoral infiltration of T cells and neutrophils. However,
according to our unpublished data, the neutrophils infil-
trating the tumor region are more likely to be N2-type
protumoral neutrophils, rather than classical N1-type
antitumoral neutrophils. We suspect that the reason for
this conflict may be that there were too many stage I
and stage II patients (67.1% vs 61.5% in our study) and
no stage IV patients, even though there was no signifi-
cant difference in the cohort distribution. Perhaps the
protumoral function of T cell infiltration is dominant
only in the early stages of cancer progression [23]. As
the disease progresses, the influence of CXCL5 on tumor
cells becomes the dominant cause of cancer. Further-
more, our results revealed that CXCL5 is an independ-
ent prognostic factor for DFS, but not for OS. This may
be because not all of the patients died from cancer
(See figure on previous page.)
Fig. 6 The CXCL5/CXCR2 axis regulates CRC cell invasion through the AKT/GSK3β/β-catenin/MMP7 pathway. a & b CXCL5 promotes CRC cell
invasion in a CXCR2-dependent manner in HCT116. Inhibition of CXCL5 reverses this process in a CXCR2-dependent manner in SW480. Scale, 200 μm.
Data are presented as the mean ± SD. c Immunofluorescence images show that CXCL5 promotes translocation of β-catenin in a CXCR2-dependent
manner in HCT116. Inhibition of CXCL5 reverses this process in a CXCR2-dependent manner in SW480. Scale, 50 μm. d The inhibitory effects of
β-catenin- shRNA on β-catenin in HCT116CXCL5 and SW480 cells. Scale, 50 μm. e & f Inhibition of β-catenin decreases the invasion of CRC cells. Scale,
200 μm. Data are presented as the mean ± SD. g & h CXCL5/CXCR2 enhances the expression of MMP7 through activation of the AKT/GSK3β/β-catenin
pathway. i & j Inhibition of the AKT pathway (LY294002) instead of the ERK pathway (U0126) reverses the activation of GSK3β/β-catenin
and upregulates the expression of MMP7. *P < 0.05, **P < 0.01, ***P < 0.001
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recurrence in the OS group. Some patients may have
died from cardiovascular disease. Taken together, these
data indicate that CXCL5 is highly expressed in CRC tis-
sues and predicts a poor prognosis for CRC patients.
We also observed that CXCL5 was primarily expressed
in tumor lesions, rather than the mesenchyme of cancer
tissue, and CRC cell lines were capable of secreting
CXCL5. This result indicates that the effect of CXCL5
may likely depend on an autocrine signaling pathway in
CRC, rather than being fibroblast-dependent as reported
in other types of cancer [15]. To further understand this
process, we constructed CRC cell lines that over-
expressed or under-expressed CXCL5 and employed in
vivo nude mouse models to elucidate the effects of
CXCL5 on CRC liver metastasis. Upregulated expression
of CXCL5 increased CRC-derived liver metastasis in the
Fig. 7 CXCL5/CXCR2 promotes CRC liver metastasis in vivo and schematic diagram. a & c Representative images of liver metastasis in the
indicated HCT116 and SW480 cells in vivo. Scale, 100 μm. Six mice are included in each group. b & d The number of metastatic nodules in each
indicated group. Data are presented as the mean ± SD. *P < 0.05, ***P < 0.001. e Schematic diagram shows that tumor-derived CXCL5 promotes
CRC cell migration by inducing EMT through the activation of ERK/Elk-1/Snail and enhances invasion through the activation of AKT/GSK3β signaling,
which inhibits the degradation of β-catenin. Accumulated β-catenin in the cytoplasm translocates to the nucleus to promote the expression of MMP7,
which facilitates cell invasion
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nude mouse model, which was dependent on CXCR2. In
line with these results, in vitro experiments also showed
that ectopic expression of CXCL5 promoted CRC cell
migration and invasion.
EMT is characterized as a dynamic and reversible bio-
logical behavior [19, 24]. When cancer cells escape from
the primary site to metastasis, subsets of cancer cells
undergo a morphological conversion from an epithelial-
like phenotype to a mesenchyme-like phenotype [25]. This
process is characterized by the loss of epithelial cell junc-
tion proteins, such as E-cadherin, and an upregulation of
mesenchymal markers, such as Vimentin and N-cadherin
[26]. In this study, we found that CRC cells with high
levels of CXCL5 expressed low levels of E-cadherin and
ZO-1 and high levels of N-cadherin and Vimentin. The
inhibition of CXCR2 was able to reverse this process.
CXCR2 was initially recognized as a G protein-coupled
transmembrane chemokine receptor involved in a variety
of pathways, such as the ERK, PI3K/AKT, JNK and STAT3
pathways [27]. In our study, we verified that both the ERK
and AKT pathways can be activated by CXCL5/CXCR2.
We next investigated that inhibition of the ERK pathway
instead of AKT pathway significantly leads to the alter-
ation of EMT markers. These results indicate that
CXCL5/CXCR2 may induce EMT through the ERK path-
way. It has been reported that ERKs can activate several
downstream transcription factors through phosphoryl-
ation to control the expression of specific genes [28]. Elk-
1 is one of those downstream transcription factors [29]. In
our study, we confirmed that inhibition of the ERK path-
way leads to the downregulation of pElk-1, which is ac-
companied by the suppression of Snail.
Snail is an important transcription factor that acts as a
repressor of E-cadherin expression and an inducer of EMT
in various types of cancer [30]. Here, we show that Snail is
upregulated upon activation of the CXCL5/CXCR2 axis.
Furthermore, the knock-down of Snail can reverse
CXCL5/CXCR2-induced EMT in CRC cells. Additionally,
inhibition of the ERK pathway, rather than the AKT path-
way, eliminates the effects of the CXCL5/CXCR2 signaling
axis on Snail. These data indicate that CXCL5/CXCR2 in-
duces EMT via the ERK/Elk-1/Snail pathway in CRC cells.
Another important finding of our study was that the
activation of the AKT pathway by the CXCL5/CXCR2
axis may be involved in promoting CRC cell invasion.
We found that the CXCL5/CXCR2 axis was capable of
promoting CRC cell invasion, but the mechanisms be-
hind this were unclear. MMPs are overexpressed in
many cancers and are capable of mediating invasion and
metastasis via ECM degradation [31]. It has been re-
ported that MMP7 is a critical factor in the regulation of
CRC cell invasion [32]. In our investigation, we revealed
that CXCL5/CXCR2 was responsible for the potentiation
of MMP7 expression and the inhibition of the AKT
pathway, and the inhibitor LY294002 instead of U0126
interfered with this process. GSK3β is a downstream
effector of AKT, and pAKT can suppress the function of
GSK3β by phosphorylating its serine residue [24].
GSK3β is a key component of the destruction complex
that facilitates the phosphorylation of β-catenin in CRC
[33]. Phosphorylated β-catenin can be recognized by β-
TrCP, which ubiquitinates pβ-catenin, and the ubiquiti-
nated pβ-catenin is then degraded by proteasomes [34].
Here, we report that activation of the AKT pathway en-
hances the phosphorylation of downstream GSK3β and
the expression of total β-catenin in CRC cells, perhaps
because the phosphorylation of GSK3β results in the
separation of the destruction complex and stabilization
of total β-catenin. Additionally, we also found that the
CXCL5/CXCR2 axis is capable of enhancing the trans-
location of β-catenin from the cytoplasm to the nucleus
where β-catenin can bind to several promoters, includ-
ing MMP7. Moreover, knock-down of β-catenin in CRC
cells decreases the number of invading cells. Altogether,
these results demonstrate that the CXCL5/CXCR2 axis
promotes CRC cell invasion through the AKT/
GSK3β/β-catenin/MMP7 pathway.
Although the function of CXCL5/CXCR2 on tumor me-
tastasis is confirmed in vivo. however, it is difficult to
translate the data acquired in vivo to human totally. Be-
cause there are at least two chemokines, CXCL5 and
CXCL6, which are able to bind to CXCR2 in human [35].
While CXCL5 and CXCL6, also called LIX or GCP-2, are
the same chemokine in mice. Human CXCL5 and CXCL6
are homologically related to CXCL5 in mice [36]. In
addition, mice don’t have CXCL8 but CXCL8 and human
CXCL6 are the only ligands to bind to both CXCR1 and
CXCR2 in human [37, 38]. Thus upregulating CXCL5 ex-
pression in mice may have a more drastic effect than up-
regulation of only one of the three chemokines in human.
Conclusion
In conclusion, our results indicate that CXCL5 is over-
expressed in CRC, which is predictive of a poor progno-
sis for CRC patients. We also demonstrate a novel role
for CXCL5 in the induction of EMT and promotion of
CRC cell migration through the ERK/Elk-1/Snail path-
way in a CXCR2-dependent manner. Furthermore, we
reveal that CXCL5/CXCR2 can potentiate CRC cell
invasion via the AKT/GSK3β/β-catenin/MMP7 pathway
rather than the ERK pathway. Thus, inhibition of the
CXCL5/CXCR2 signaling pathway may be a promising
target for therapies for CRC patients.
Methods
Chemokine microarray analysis
The profiles of chemokines were examined using a
Human Chemokine Antibody Array C1 kit (RayBiotech,
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USA). This experiment was performed according to the
manufacturer’s instructions and supported by the
BioTNT Corporation, Shanghai. The levels of certain
chemokines in the tumor tissues were more than
2.0-fold higher, which we defined as “significant upregu-
lation”. We also defined a 1.5- to 2.0-fold change as
“insignificant upregulation”, a 0.67- to 1.5-fold change as
“no difference”, a 0.5- to 0.67-fold change as “nonsignifi-
cant downregulation”, and a less than 0.5 change as
“significant downregulation”.
Patients and follow-up
Two independent cohorts of colorectal cancer patients
are enrolled in our study. All these patients were diag-
nosed specifically by pathology as CRC (before or after
surgery) and treated with laparoscopic surgery in
Minimally Invasive Surgery Centre, Ruijin Hospital,
Shanghai Jiaotong University. Ethics approval for use of
human specimen was obtained from the Biomedical
Ethics Committee of Ruijin Hospital. All the tumor tis-
sues and paired peritumoral normal tissues contained in
Cohort 1 were collected from patients undergoing
operation between Nov.2015 and Mar.2016. Tissues of
Cohort 2 were collected from patients undergoing oper-
ation from 2010 to 2011. Clinical and pathological data
were collected. All the patients who had received pre-
operative treatment such as radiation or chemotherapy
were excluded. Pathological staging of CRC tumor was
performed in accordance to the TNM classification [39].
The follow-up data were acquired at 2-month intervals
through outpatient visits, telephone calls, or office visits.
The follow-up data were ceased in August 2015.
Cell lines
The human CRC cell lines used in our study were pur-
chased from the American Type Culture Collection
(ATCC, USA) and preserved in liquid nitrogen by the
Shanghai Digestive Surgery Institute and routinely tested
for mycoplasma contamination using PCR. These cell
lines were authenticated prior to being used in our study.
The SW480 cell line was cultured using Leibovitz’s L-15
medium, and the HCT116 cell line was cultured using
McCoy’s 5A medium with 10% FBS, penicillin (107 U/L),
and streptomycin (10 mg/L) at 37 °C with 5% CO2 in an
incubator.
Liver metastasis in in vivo nude mouse models
Animal experiments were performed in accordance with
the ethical guidelines issued by the Ethics Committee of
Shanghai Jiaotong University. Male BALB/c nu/nu mice
(4 weeks old) were purchased from the Chinese Academy
of Sciences, Shanghai and raised in a specific-pathogen-free
environment. For the construction of the liver metastasis
model, 6 nude mice were included in each group
(HCT116CXCL5, HCT116shCXCR2, HCT116CXCL5-shCXCR2
and HCT116vector groups as well as SW480shCXCL5,
SW480shCXCR2, and SW480shCXCL5-shCXCR2, and
SW480shRNA groups were injected into the spleens of the
mice). After being anesthetized with an intraperitoneal in-
jection of 1% pentobarbital sodium (50 mg/kg), abdominal
surgeries were performed to expose the spleen and slowly
inject it with 1×107 cells suspended in 150 μL PBS. The
spleen was then returned to the abdominal cavity, and the
abdomen was closed. The cells were then transported by
the circulatory system to the liver to spontaneously form
metastatic lesions. The mice were euthanized by cervical
decapitation 6 weeks after injection to examine the liver
metastases of tumor cells. Liver metastases were confirmed
by HE staining.
Statistical analysis
All of the statistical analysis were performed using SAS
8.0, SPSS 16.0 or R software 3.1.2 (R Core Team). The
Pearson χ2 test and Fisher’s exact probability method
were used to analyze the relationship between CXCL5
and clinical features. Overall Survival and Disease Free
Survival curves were plotted using the Kaplan-Meier
method, and differences between the two groups were
determined using a log-rank test. Univariate and multi-
variate analyses were performed using the Cox regres-
sion model. A nomogram was formulated based on the
results of the multivariate analysis and plotted using R
software. All experiments were performed in triplicate.
P < 0.05 was considered to be statistically significant.
Additional files
Additional file 1: Figure S1. X-tile analysis of survival data in CRC
patients reveals a continuous distribution based on CXCL5 staining score.
The plot shows the χ2 log-rank values produced when dividing the
cohort with one cut-point, producing high, and low subsets. The X-axis
represents all potential cut-points from low to high (left to right) that
defines a low subset, whereas the Y-axis represents cut-points from high
to low (top to bottom), that defines a high subset. Red coloration of
cut-point indicates an inverse correlation with survival, whereas green
coloration represents direct associations (A). The optimal cut-point occurs
at the brightest pixel (red). The cut-point highlighted by the white circle
in A is shown on a histogram of the entire cohort (B), and a Kaplan-Meier
plot (C, low subset grey, high subset light green). (TIF 4341 kb)
Additional file 2: Figure S2. Increased expression of CXCL5 in CRC
tissues and calibration curve. A: An immunoblot showing that CXCL5 is
overexpressed in cancer tissues compared with the peritumoral normal
tissues. B: Calibration plots for predicting DFS 3 years after surgery.
C: Calibration plots for predicting DFS 5 years after surgery. (TIF 2163 kb)
Additional file 3: Tables and Methods. Table S1, shRNA Sequences;
Table S2, antibodies for immunoblot; Table S3, antibodies for
immunofluorescence; Table S4, correlations between CXCL5 expression
and clinical characteristics in CRC patients; Table S5, univariate and
multivariate analyses of CXCL5 expression in CRC patients; Table S6,
pathological stages of patients in Fig. 2A&B; Supplementary methods.
(DOC 178 kb)
Additional file 4: Figure S3. The expression of CXCL5 in CRC cell lines
and CXCL5/CXCR2 promotes CRC cell migration through the induction
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of EMT. A: ELISAs examining CXCL5 expression levels in CRC cell lines
supernatants. B: Immunofluorescence analysis verifying the effects of
upregulation of CXCL5 using a CXCL5-vector and shRNA-inhibition of
CXCL5 and CXCR2. Magnification, 400×. C: Morphological changes in the
indicated cells. Magnification, 200×. Scale, 200 μm. (TIF 16430 kb)
Additional file 5: Figure S4. CXCL5/CXCR2 induces EMT in CRC cells
via the ERK/Elk-1 pathway. A & B: Morphological changes after treatment
with LY294002 or U0126 in HCT116 and SW480 cells. Scale, 200 μm. C &
E: Representative images of the transwell migration assays after treatment
with LY294002 or U0126 in HCT116 and SW480 cells. Scale, 200 μm.
Treatment with U0126 decreases the migrated cell number. D & F: The
column graph displays the migrated cell number of the indicated cells.
Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
(TIF 12172 kb)
Abbreviations
BCA: Bicinchoninic acid; CRC: Colorectal carcinoma; EMT: Epithelial
mesenchymal transition; GFP: Green fluorescence protein; shRNA: Short
hairpin RNA
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